专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012067427A3 PHARMACEUTICAL COMPOSITION CONTAINING LK8 PROTEIN AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING DIABETIC RETINOPATHY OR AGE-RELATED MACULAR DEGENERATION 审中-公开
公开(公告)号：WO2012067427A3
公开(公告)日：2012-09-13
申请号：PCT/KR2011008761
申请日：2011-11-16
申请人： MOGAM BIOTECH RES INST , AHN JIN-HYUNG , LIM YANG MI , KIM JEONG HUN , YU HYUN-KYUNG , CHOI HANA , YOON YEUP , HWANG YU KYEONG
发明人： AHN JIN-HYUNG , LIM YANG MI , KIM JEONG HUN , YU HYUN-KYUNG , CHOI HANA , YOON YEUP , HWANG YU KYEONG
IPC分类号： A61K38/16 , A61P3/10 , A61P27/00 , A61P27/02
CPC分类号： A61K38/16
摘要： The present invention relates to a pharmaceutical composition containing, as an active ingredient, LK8 protein having an amino acid sequence depicted in sequence identification number 1, for preventing or treating diabetic retinopathy or age-related macular degeneration. The LK8 protein has an effect of inhibiting a bond between fibronectin and vascular endothelial cells, and therefore, can be valuably used as a composition for preventing or treating diabetic retinopathy or age-related macular degeneration.

2. 发明申请

WO2008153366A3 METHOD FOR MANUFACTURING ACTIVE RECOMBINANT BLOOD COAGULATION FACTOR IX 审中-公开
标题翻译：制备活性重组血液凝血因子IX的方法
公开(公告)号：WO2008153366A3
公开(公告)日：2009-03-19
申请号：PCT/KR2008003377
申请日：2008-06-16
申请人： MOGAM BIOTECH RES INST , KIM JUNG-SEOB , LIM INHWAN , CHOI MURIM , LEE GUE-HWA , YOON YEUP
发明人： KIM JUNG-SEOB , LIM INHWAN , CHOI MURIM , LEE GUE-HWA , YOON YEUP
IPC分类号： C12N15/85 , C12N15/11
CPC分类号： C12N9/647 , C12N9/644 , C12Y304/21022
摘要： The present invention provides an expression vector producing a recombinant blood coagulation factor IX (FIX), an animal cell line transfected with the expression vector, an optimized medium for animal cell culture able to maximize the production of active FIX (aFIX), and an optimized culture method to culture the animal cell line in the optimized medium.
摘要翻译：本发明提供了产生重组血液凝固因子IX（FIX）的表达载体，用表达载体转染的动物细胞系，能够使活性FIX（aFIX）产生最大化的动物细胞培养物的优化培养基，培养方法，在优化培养基中培养动物细胞系。

3. 发明申请

WO2013168965A3 VACCINE COMPOSITION FOR PREVENTING STAPHYLOCOCCUS AUREUS INFECTION 审中-公开
标题翻译：用于预防斑马鱼黄疸感染的疫苗组合物
公开(公告)号：WO2013168965A3
公开(公告)日：2014-01-16
申请号：PCT/KR2013003957
申请日：2013-05-07
申请人： MOGAM BIOTECH RES INST , PUSAN NAT UNIV IND COOP FOUND
发明人： LEE BOK LUEL , KENJI KUROKAWA , JUNG DONG-JUN , AN JANG-HYUN , JEON YU-JIN , KIM NA HYANG , KAZUE TAKAHASHI , KIM EUNMI , AHN DONG HO
IPC分类号： A61K39/395 , A61K38/16 , A61K38/17 , A61P31/00 , A61P31/04
CPC分类号： A61K39/085 , A61K39/00 , A61K2039/575 , C07K16/1271
摘要： The present invention relates to a vaccine composition for preventing staphylococcus aureus infection containing, as an active ingredient, a ribitol-phosphate which has been modified only by a beta-configuration in N-Acetylglucosamine (GlcNAc), a repeating unit of the ribitol-phosphate, or a wall teichoic acid (WTA) containing the repeating unit. The composition according to the present invention contains a coupling motif (an epitope) for an anti-WTA antibody, and thus can be effectively used as a vaccine composition or to prevent staphylococcus aureus infection by generating anti-WTA antibody.
摘要翻译：本发明涉及一种用于预防金黄色葡萄球菌感染的疫苗组合物，其含有仅通过N-乙酰葡糖胺（GlcNAc）中β-构型修饰的核糖醇 - 磷酸的活性成分，核糖醇 - 磷酸重复单元，或含有重复单元的壁磷壁酸（WTA）。根据本发明的组合物含有用于抗WTA抗体的偶联基序（表位），因此可以有效地用作疫苗组合物或通过产生抗WTA抗体来预防金黄色葡萄球菌感染。

4. 发明申请

WO2012115474A2 NOVEL VARICELLA-ZOSTER VIRUS STRAINS, AND CHICKEN POX AND HERPES ZOSTER VIRUS VACCINE USING SAME 审中-公开
标题翻译：新鲜的VARICELLA-ZOSTER VIRUS菌株和鸡肉酱和其它使用相同的病毒的ZOSTER VIRUS VACCINE
公开(公告)号：WO2012115474A2
公开(公告)日：2012-08-30
申请号：PCT/KR2012001408
申请日：2012-02-24
申请人： MOGAM BIOTECH RES INST , KIM GEUN HEE , KWON SHI NAE , LEE CHAN HEE , YOON YEOP
发明人： KIM GEUN HEE , KWON SHI NAE , LEE CHAN HEE , YOON YEOP
IPC分类号： C12N15/33 , A61K39/25 , C07K14/04 , C12N7/00 , C12N15/63
CPC分类号： C07K14/005 , A61K39/12 , A61K39/25 , C12N7/00 , C12N2710/16721 , C12N2710/16722 , C12N2710/16734
摘要： The present invention relates to novel varicella-zoster virus strains and to a chicken pox and herpes zoster virus vaccine using same. More particularly, the present invention relates to genome DNA of VZV MVA06 isolated from a Korean patient, to an open reading frame (ORF) thereof, to a protein coded by the genome DNA of VZV MVA06 and the ORF thereof, and to a vaccine composition which contains the protein as an active ingredient.
摘要翻译：本发明涉及新型水痘带状疱疹病毒株和使用其的水痘和带状疱疹病毒疫苗。更具体地，本发明涉及从韩国患者分离到其开放阅读框（ORF）的VZV MVA06与由VZV MVA06的基因组DNA及其ORF编码的蛋白质的基因组DNA，以及疫苗组合物其含有蛋白质作为活性成分。

5. 发明申请

WO2012067427A2 PHARMACEUTICAL COMPOSITION CONTAINING LK8 PROTEIN AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING DIABETIC RETINOPATHY OR AGE-RELATED MACULAR DEGENERATION 审中-公开
标题翻译：含有LK8蛋白作为活性成分的药物组合物，用于预防或治疗糖尿病性肾病或与年龄相关的恶化
公开(公告)号：WO2012067427A2
公开(公告)日：2012-05-24
申请号：PCT/KR2011008761
申请日：2011-11-16
申请人： MOGAM BIOTECH RES INST , AHN JIN-HYUNG , LIM YANG MI , KIM JEONG HUN , YU HYUN-KYUNG , CHOI HANA , YOON YEUP , HWANG YU KYEONG
发明人： AHN JIN-HYUNG , LIM YANG MI , KIM JEONG HUN , YU HYUN-KYUNG , CHOI HANA , YOON YEUP , HWANG YU KYEONG
IPC分类号： A61K38/16 , A61P3/10 , A61P27/00 , A61P27/02
CPC分类号： A61K38/16
摘要： The present invention relates to a pharmaceutical composition containing, as an active ingredient, LK8 protein having an amino acid sequence depicted in sequence identification number 1, for preventing or treating diabetic retinopathy or age-related macular degeneration. The LK8 protein has an effect of inhibiting a bond between fibronectin and vascular endothelial cells, and therefore, can be valuably used as a composition for preventing or treating diabetic retinopathy or age-related macular degeneration.
摘要翻译：本发明涉及含有用于预防或治疗糖尿病性视网膜病变或年龄相关性黄斑变性的具有序列号1所示氨基酸序列的LK8蛋白作为活性成分的药物组合物。 LK8蛋白具有抑制纤连蛋白与血管内皮细胞之间的结合的作用，因此可以有价值地用作预防或治疗糖尿病性视网膜病变或年龄相关性黄斑变性的组合物。

6. 发明申请

WO0214525A3 EXPRESSION VECTOR USING FOR ANIMAL CELL 审中-公开
标题翻译：用于动物细胞的表达载体
公开(公告)号：WO0214525A3
公开(公告)日：2003-11-20
申请号：PCT/KR0101285
申请日：2001-07-27
申请人： MOGAM BIOTECH RES INST , PAN GEN BIOTECH LAB INC , KIM JONG-MOOK , KIM JUNG-SEOB , OH SUN-MO , YOON JAE-SEUNG , BAEK KWANG-HEE , CHUNG SOO-IL , PARK DOO-HONG , YOON YEUP
发明人： KIM JONG-MOOK , KIM JUNG-SEOB , OH SUN-MO , YOON JAE-SEUNG , BAEK KWANG-HEE , CHUNG SOO-IL , PARK DOO-HONG , YOON YEUP
IPC分类号： C12N15/09 , C07K14/47 , C07K14/595 , C07K14/71 , C12N15/85 , C12P21/02
CPC分类号： C12N15/85 , C07K14/4717 , C07K14/595 , C07K14/71 , C12N2830/46
摘要： The present invention relates to a expression vector for animal cells. Specifically, the present invention relates to a expression vector, pMS vector, pSG vector and pMSG, vector, including the human beta -globin 5' MAR complementary sequence or/and the transcription termination site of gastrin gene. An expression system using the expression vector of the present invention can successfully produce recombinant proteins in various animals cells and recombinant protein having a unique structure and function.
摘要翻译：本发明涉及动物细胞的表达载体。具体而言，本发明涉及表达载体pMS载体，pSG载体和pMSG载体，包括人β-珠蛋白5'MAC互补序列或/和胃泌素基因的转录终止位点。使用本发明的表达载体的表达系统可以成功地在各种动物细胞中产生重组蛋白质，并具有独特的结构和功能的重组蛋白质。

7. 发明申请

WO2011129468A1 HEXON ISOLATED FROM SIMIAN ADENOVIRUS SEROTYPE 19, HYPERVARIABLE REGION THEREOF AND CHIMERIC ADENOVIRUS USING THE SAME 审中-公开
标题翻译：来自SIMIAN ADENOVIRUS SEROTYPE 19的HEXON，其优质的区域和使用它的CHIMERIC ADENOVIRUS
公开(公告)号：WO2011129468A1
公开(公告)日：2011-10-20
申请号：PCT/KR2010002298
申请日：2010-04-14
申请人： MOGAM BIOTECH RES INST , LEE KYUHYUN , YUN SEONGTAE , KOH DAEKYUNG , LEE HONG-KYU , JO EUI-CHEOL
发明人： LEE KYUHYUN , YUN SEONGTAE , KOH DAEKYUNG , LEE HONG-KYU , JO EUI-CHEOL
IPC分类号： C07K14/075 , C12N15/34 , C12N15/861
CPC分类号： C12N7/00 , A61K39/0011 , A61K2039/5256 , C07K14/005 , C12N15/86 , C12N2710/10321 , C12N2710/10322 , C12N2710/10332 , C12N2710/10342 , C12N2710/10343 , C12N2710/10345 , C12N2810/6018
摘要： Novel hexon isolated from simian adenovirus serotype 19 encoded in the polynucleotide defined as SEQ ID NO: 3, hepervariable region thereof, chimeric adenovirus comprising the same, and therapeutic use thereof provides a solution to the problem of safety and effective systemic treatment for developing gene therapeutic agents using adenovirus.
摘要翻译：由定义为SEQ ID NO：3的多核苷酸编码的猿猴腺病毒血清型19分离的新型六邻体，其全变体区，包含该多核苷酸的嵌合腺病毒及其治疗用途提供了用于开发基因治疗的安全性和有效全身治疗问题的解决方案使用腺病毒的药剂。

8. 发明申请

WO2009008645A2 LINEAR DOUBLE-STRANDED RNA MOLECULE INTERFERING WITH DIFFERENT TARGET GENES 审中-公开
标题翻译：线性双链RNA分子与不同目标基因的干扰
公开(公告)号：WO2009008645A2
公开(公告)日：2009-01-15
申请号：PCT/KR2008003982
申请日：2008-07-07
申请人： MOGAM BIOTECH RES INST , KIM MEEHYEIN , SHIN DUCKHYANG , LEE HYEON , KIM SOO IN , YOON YEUP
发明人： KIM MEEHYEIN , SHIN DUCKHYANG , LEE HYEON , KIM SOO IN , YOON YEUP
IPC分类号： C12N15/09 , C12P19/34
CPC分类号： C12N15/111 , C12N2310/111 , C12N2310/14 , C12N2310/51
摘要： A linear double-stranded RNA molecule, which comprises two or more consecutively or convergently linked short interfering RNAs (siRNAs) each reducing the expression of one of different target genes, and a recombinant expression vector comprising double-stranded DNA sequence expressing the linear double-stranded RNA molecule are provided. The linear double-stranded RNA molecule or the recombinant expression vector is useful for a method of reducing expression of target genes in a cell, the method comprising introducing the linear double-stranded RNA molecule or the recombinant expression vector into the cell, whereby the encoded siRNAs target different genes and reduce expression of the target genes. It was also proved that effective gene silencing activity can be induced when each siRNA unit within the linear double-stranded RNA molecule has 18 to 24 nucleotides and, additionally, the gene silencing activity is not affected by inverted orientation of an siRNA.
摘要翻译：线性双链RNA分子，其包含两个或更多个连续或趋向连接的短干扰RNA（siRNA），每个短干扰RNA减少一个不同靶基因的表达;以及重组表达载体，其包含表达线性双链RNA的双链DNA序列，提供了双链RNA分子。线性双链RNA分子或重组表达载体可用于减少细胞中靶基因表达的方法，该方法包括将线性双链RNA分子或重组表达载体引入细胞，由此编码 siRNA靶向不同的基因并减少靶基因的表达。还证明当线性双链RNA分子内的每个siRNA单元具有18至24个核苷酸时，可以诱导有效的基因沉默活性，此外，基因沉默活性不受siRNA反向取向的影响。

9. 发明申请

WO0210396A9 GENE EXPRESSION SYSTEM FOR MASS PRODUCTION OF HEPATITIS C VIRAL RNA-DEPENDENT RNA POLYMERASE AND ENZYME ASSAY USING FUSION PROTEIN EXPRESSED THEREFROM 审中-公开
标题翻译：用于生产乙型肝炎病毒RNA依赖性RNA聚合酶的基因表达系统和使用其表达的融合蛋白的酶检测
公开(公告)号：WO0210396A9
公开(公告)日：2005-04-14
申请号：PCT/KR0000825
申请日：2000-07-28
申请人： MOGAM BIOTECH RES INST , HANMI PHARM IND CO LTD , PROTHEON CO LTD , MIN MI-KYUNG , KIM HA-JUNG , CHUNG SOO-IL , JIN SEUNG-WON , CHOI SEONG IL , SEONG BAIK-LIN
发明人： MIN MI-KYUNG , KIM HA-JUNG , CHUNG SOO-IL , JIN SEUNG-WON , CHOI SEONG IL , SEONG BAIK-LIN
IPC分类号： C12N15/51 , C12N15/70 , C12N1/20 , C12N15/62
CPC分类号： C12N15/70
摘要： The present invention relates to gene expression system for mass production of hepatitis c viral rna-dependent rna polymerase and enzyme assay using fusion protein expressed therefrom. Particularly, the present invention relates to the gene expression system which uses N-terminal domain of E.coli lysyl-tRNA synthetase as fusion partner and mass-produces HCV RNA-depedent RNA polymerase(NS5B) in water-soluble type, and the in vitro enzyme assay for measuring the polymerase activity. The gene expression system of the present invention can mass-produce the HCV RNA polymerase in water-soluble type, so it is useful for a construction of in vitro assay system for HCV enzyme proteins and a screening of antiviral agents. In addition, the in vitro assay for measuring the HCV RNA polymerase of the present invention can be used to develop HCV inhibitory agents.
摘要翻译：本发明涉及用于大量生产丙型肝炎病毒rna依赖性rna聚合酶的基因表达系统和使用由其表达的融合蛋白的酶测定法。特别地，本发明涉及使用大肠杆菌赖氨酰-tRNA合成酶的N-末端结构域作为融合配偶体的大规模生产水溶性HCV RNA潜在RNA聚合酶（NS5B）的基因表达系统，用于测量聚合酶活性的体外酶测定。本发明的基因表达系统可以大量生产水溶性HCV RNA聚合酶，因此可用于构建HCV酶蛋白的体外测定系统和抗病毒剂的筛选。此外，用于测量本发明的HCV RNA聚合酶的体外测定法可用于开发HCV抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式